Organon presented real-world evidence showing its biosimilar HADLIMA had a low switchback rate (1.3%) from originator HUMIRA in the VA system, generating $132 million in savings. This filing highlights the potential for biosimilars to drive healthcare cost reductions and expand patient access, positively impacting Organon's market position in the biosimilar space.
Organon disclosed real-world data from the VA Healthcare System demonstrating the successful transition of over 16,000 patients from the originator drug HUMIRA to its biosimilar, HADLIMA. The key findings were a remarkably low 1.3% switchback rate and an estimated $132 million in savings for the healthcare system. This matters because it provides strong evidence for the efficacy and cost-effectiveness of biosimilars, bolstering Organon's position in this growing market. Organon (OGN) benefits directly from this positive data, while AbbVie (ABBV), the originator of HUMIRA, faces continued pressure from biosimilar erosion. In the short term, this reinforces investor confidence in Organon's biosimilar strategy. Long-term, it signals a broader shift towards biosimilar adoption, which could impact the entire pharmaceutical industry by driving down costs and increasing access to treatments, posing both opportunities for biosimilar manufacturers and risks for originator drug companies.